DK0625050T3 - TGF-BETA to improve nerve tissue regeneration - Google Patents

TGF-BETA to improve nerve tissue regeneration

Info

Publication number
DK0625050T3
DK0625050T3 DK92925330T DK92925330T DK0625050T3 DK 0625050 T3 DK0625050 T3 DK 0625050T3 DK 92925330 T DK92925330 T DK 92925330T DK 92925330 T DK92925330 T DK 92925330T DK 0625050 T3 DK0625050 T3 DK 0625050T3
Authority
DK
Denmark
Prior art keywords
tgf
beta
tissue regeneration
nerve tissue
improve nerve
Prior art date
Application number
DK92925330T
Other languages
Danish (da)
Inventor
Peter Gluckman
Karoly Nikolics
Christopher Williams
Original Assignee
Auckland Uniservices Ltd
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auckland Uniservices Ltd, Genentech Inc filed Critical Auckland Uniservices Ltd
Application granted granted Critical
Publication of DK0625050T3 publication Critical patent/DK0625050T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To provide a method for treating central nervous system injury or disorder. <P>SOLUTION: The method is characterized by increasing an effective amount of a transforming growth factor β1 (TGF-β1) in the central nervous system of the subjects. The method is effective for suppressing injury possible to follow after the injury to the central nervous system in the absence of the administration of the TGF-β1. <P>COPYRIGHT: (C)2004,JPO
DK92925330T 1991-11-22 1992-11-20 TGF-BETA to improve nerve tissue regeneration DK0625050T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ24069691 1991-11-22
PCT/US1992/009974 WO1993009802A2 (en) 1991-11-22 1992-11-20 Tgf-beta to improve neural outcome

Publications (1)

Publication Number Publication Date
DK0625050T3 true DK0625050T3 (en) 1999-10-25

Family

ID=19923808

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92925330T DK0625050T3 (en) 1991-11-22 1992-11-20 TGF-BETA to improve nerve tissue regeneration

Country Status (9)

Country Link
EP (1) EP0625050B1 (en)
JP (2) JP4101284B2 (en)
AT (1) ATE178801T1 (en)
CA (1) CA2122058C (en)
DE (1) DE69228949T2 (en)
DK (1) DK0625050T3 (en)
ES (1) ES2133333T3 (en)
GR (1) GR3030651T3 (en)
WO (1) WO1993009802A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7166277B1 (en) 1991-07-08 2007-01-23 Neurospheres Holdings Ltd. Remyelination of neurons using multipotent neural stem cell progeny
US5980885A (en) * 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. Growth factor-induced proliferation of neural precursor cells in vivo
US6399369B1 (en) 1991-07-08 2002-06-04 Neurospheres Holdings Ltd. Multipotent neural stem cell cDNA libraries
US5851832A (en) * 1991-07-08 1998-12-22 Neurospheres, Ltd. In vitro growth and proliferation of multipotent neural stem cells and their progeny
US6071889A (en) * 1991-07-08 2000-06-06 Neurospheres Holdings Ltd. In vivo genetic modification of growth factor-responsive neural precursor cells
US6294346B1 (en) 1991-07-08 2001-09-25 Neurospheres Holdings, Ltd. Use of multipotent neural stem cells and their progeny for the screening of drugs and other biological agents
US6497872B1 (en) 1991-07-08 2002-12-24 Neurospheres Holdings Ltd. Neural transplantation using proliferated multipotent neural stem cells and their progeny
US7361505B1 (en) 1991-07-08 2008-04-22 Neurospheres Holdings Ltd. Multipotent neural stem cell compositions
US5750376A (en) * 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US5650396A (en) * 1994-03-15 1997-07-22 Celtrix Pharmaceuticals, Inc. Methods of modulating inflammatory cytokines in the CNS using TGF-β
KR20000064752A (en) * 1996-03-22 2000-11-06 더 제네랄 호스피탈 코포레이션 Administration of Polypeptide Growth Factor after Expression of Central Nervous System Ischemia or Trauma
US7544511B2 (en) 1996-09-25 2009-06-09 Neuralstem Biopharmaceuticals Ltd. Stable neural stem cell line methods
WO1999002139A1 (en) * 1997-07-10 1999-01-21 Keith Baker Methods for universally distributing therapeutic agents to the brain
US5968829A (en) * 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
US8293488B2 (en) 2002-12-09 2012-10-23 Neuralstem, Inc. Method for screening neurogenic agents
AU2003293409A1 (en) 2002-12-09 2004-06-30 Karl K. Johe Method for discovering neurogenic agents
CN103146649B (en) 2004-06-09 2018-05-22 爱丁堡大学管理处 Neural stem cell
KR101429284B1 (en) 2004-11-17 2014-08-11 뉴럴스템, 인크. Transplantation of Human Neural Cells for Treatment of Neurodegenerative Conditions
EP3187581A1 (en) 2008-12-23 2017-07-05 BOCO Silicon Valley, Inc. Target populations of oligodendrocyte precursor cells and methods of making and using same
US9540611B2 (en) 2010-07-28 2017-01-10 Neuralstem, Inc. Methods for treating and/or reversing neurodegenerative diseases and/or disorders
JP6983069B2 (en) 2014-10-20 2021-12-17 ニューラルステム， インコーポレイテッド Stable neural stem cells containing exogenous polynucleotides encoding growth factors and methods of their use

Also Published As

Publication number Publication date
EP0625050B1 (en) 1999-04-14
ES2133333T3 (en) 1999-09-16
GR3030651T3 (en) 1999-10-29
DE69228949T2 (en) 1999-09-16
CA2122058C (en) 2001-07-31
CA2122058A1 (en) 1993-05-27
JP4101284B2 (en) 2008-06-18
JPH07501080A (en) 1995-02-02
ATE178801T1 (en) 1999-04-15
JP2004115532A (en) 2004-04-15
DE69228949D1 (en) 1999-05-20
WO1993009802A2 (en) 1993-05-27
EP0625050A1 (en) 1994-11-23

Similar Documents

Publication Publication Date Title
DK0625050T3 (en) TGF-BETA to improve nerve tissue regeneration
PT840601E (en) THIP FOR THE TREATMENT OF SLEEP DISORDERS
BR9306226A (en) Composition of wound healing and treatment of fibrotic disorders and method for its preparation
PT777483E (en) METHODS AND MEANS TO ADMINISTRATE DRUGS
DK1574209T3 (en) Procedure for the treatment of ophthalmic diseases
DE69232008D1 (en) Use of insulin-like growth factors and analogs to treat optic nerve disorders
DK202882A (en) PROCEDURE FOR PREPARING 1-ALKYL-2-AMINOTETRALIN DERIVATIVES
DK0774962T3 (en) Use of DHA in the treatment of dyslexia
DK586387A (en) PIPERIDE INGREDIENTS FOR TREATMENT OF PAIN CONDITIONS
ATE137965T1 (en) USE OF TOMOXETINE TO TREAT LOWER URINARY TRACT DISORDERS
DK0863760T3 (en) Use of compounds with antimineral corticoid action against drug weaning
DE69800859D1 (en) Use of moxonidine to treat neuropathic pain
DK1237562T3 (en) Process for the preparation of micania extracts containing micanolide and dihydromycanolide and use in the treatment of proliferative diseases
PT655243E (en) MELATONINE DERIVATIVES FOR USE IN THE TREATMENT OF SLEEP DISTURBANCES
ATE289809T1 (en) USE OF VALINE FOR PRODUCING A MEDICATION FOR LIVER REGENERATION
FR2725990B1 (en) WATER-SOLUBLE DERIVATIVES OF EPIPODOPHYLLOTOXIN, PROCESS FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS, AND THEIR USE FOR CANCER TREATMENTS
ATE137407T1 (en) TREATING INTRAOCULAR PRESSURE WITH A SYNERGISTIC COMBINATION
HUP9903679A2 (en) Use of olanzapine for the preparation of pharmaceutical compositions treating bipolar disorder
ATE306278T1 (en) TREATING BONE DISEASES WITH ADRENOMEDULLIN
HRP20080389A2 (en) THE USE OF R(+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL FOR THE TREATMENT OF SLEEP DISORDERS
SE9101341D0 (en) NEW MEDICINAL USE
RU97101420A (en) METHOD FOR TONZILLITIS TREATMENT
DK0538897T3 (en) Use of BMY 14802 in the treatment of anxiety in benzodiazepine-exposed patients
RU96122672A (en) ECHINAMAX. METHOD OF TREATMENT OF ASTHENIC CONDITIONS IN PHYSIOGENIC DISADAPTATIONS